By admin 
The controversy stems from an incident five weeks ago during the American Diabetes Association (ADA) 86th Scientific Sessions. While the meeting is traditionally a venue for unveiling breakthrough clinical trial data and networking among the world’s leading diabetes specialists, this year’s gathering was overshadowed by the forced removal of five prominent researchers. These specialists were intercepted by security and escorted out of the building for the "offense" of distributing reprints of a previously published editorial titled "Misguided Brushes of a Pen Continue to Dismantle." The editorial in question expressed grave concerns regarding the Trump administration’s proposed cuts to federal research funding, specifically targeting the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
In the aftermath of the evictions, the ADA leadership initially faced a firestorm of criticism on social media and internal forums, leading to a public apology and a promise of a "formal, independent review" of the incident. However, the latest development suggests that the organization is prioritizing damage control over transparency. The editorial board of Diabetes Care, the ADA’s highest-impact clinical journal, had prepared a special section intended to provide a post-mortem of the New Orleans event. This section was to include a lead editorial by the journal’s editors and several first-person accounts from the ejected scientists, detailing their treatment by security and the chilling effect such actions have on scientific advocacy.
According to sources familiar with the internal deliberations, the ADA’s executive leadership stepped in at the eleventh hour to "spike" the content. The organization’s justification for this intervention is that the publication of such accounts could "prejudice" the ongoing formal review. This explanation has been met with skepticism and outright hostility by many in the field, who view it as a convenient mechanism for silencing dissent until public interest wanes. There is also a growing rift regarding the nature of the review itself; while the ADA characterizes it as a rigorous investigation, several prominent members describe it as an opaque process controlled by the very individuals who authorized the security intervention in June.
The suppressed documents, which have since been uploaded to the open-access repository Zenodo to bypass the ADA’s gatekeeping, paint a harrowing picture of professional disrespect. In these accounts, the specialists—many of whom have dedicated decades to the ADA and held senior leadership roles—describe being treated like trespassers rather than esteemed colleagues. They argue that their "protest" was in fact a fundamental exercise in scientific communication: alerting their peers to policy shifts that threaten the future of diabetes research in the United States. The editorial originally being distributed warned that the "brushes of a pen" in Washington D.C. could erase decades of progress in treating Type 1 and Type 2 diabetes by defunding the basic science labs that serve as the pipeline for new therapies.
The political backdrop of this conflict cannot be overstated. The scientific community has grown increasingly vocal in its opposition to federal policies that deprioritize climate science, public health infrastructure, and biomedical research. For the ADA, a non-profit that relies on a delicate balance of corporate sponsorships, member dues, and federal advocacy, the decision to eject protesters was seen by critics as an attempt to remain "neutral" or "apolitical" to avoid antagonizing the administration. However, as the ejected specialists argue in their now-leaked accounts, when the "neutrality" of a medical organization involves silencing its members who are defending research budgets, that neutrality becomes a form of complicity.
The fallout has already resulted in high-profile resignations. At least one member of the ADA’s Board of Directors has stepped down in protest of the New Orleans incident, and several others have signaled that they will not renew their memberships. The blocking of the Diabetes Care editorial has only added fuel to the fire. Academic journals are generally expected to operate with a high degree of autonomy from the professional societies that own them. This "firewall" is considered essential to ensure that the science and commentary published within their pages are based on merit and the public interest rather than the branding needs of the parent organization. By breaching this firewall, the ADA leadership has risked the reputation of Diabetes Care, a journal that clinicians rely on for unbiased data and rigorous debate.
Prominent ADA members, including past presidents and recipients of the association’s highest honors, have voiced their dismay. They point out that the ADA has a long history of advocacy in Washington, and that the organization’s strength has historically come from its ability to mobilize the scientific community against threats to patient care and research. The current leadership’s pivot toward a more controlled, top-down approach is viewed by many as a betrayal of the association’s founding principles. "The ADA should be the loudest voice in the room when research funding is on the chopping block," said one former officer who requested anonymity to speak freely about the internal culture. "Instead, we are seeing a leadership that is more afraid of a few reprints in a hallway than they are of a billion-dollar cut to the NIDDK."
The move to publish the spiked content on Zenodo represents a modern form of "guerrilla" academic publishing. In the digital age, traditional hierarchies find it increasingly difficult to suppress information. The fact that the first-person accounts and the editorial are now circulating widely on social media and through listservs suggests that the ADA’s attempt to "delay" the conversation has backfired, drawing even more attention to the original controversy. The Zenodo posts include detailed descriptions of the "aggressive" posture of the security team in New Orleans and the refusal of ADA staff on-site to engage in a dialogue with the researchers.
As the formal review continues, the ADA finds itself at a crossroads. The organization must decide whether it will double down on its current trajectory—characterized by centralized control and a risk-averse approach to political advocacy—or whether it will move to restore the trust of its membership by reaffirming its commitment to editorial independence and the right of its members to dissent. The controversy is likely to dominate the discourse at upcoming regional meetings and could lead to a contested leadership transition in the coming year.
The broader scientific community is watching closely. The situation at the ADA is seen as a bellwether for how other medical societies might handle the increasing pressures of a polarized political environment. If one of the largest and most influential health organizations in the world can successfully silence its own journal editors and eject its most respected researchers, it sets a dangerous precedent for the future of scientific discourse. Conversely, if the membership successfully pushes back, it could signal a renewed era of activism for professional societies that have, for too long, remained on the sidelines of the policy battles that define their fields.
For now, the "turmoil" shows no signs of abating. The blocked editorial, titled "Silence is Not a Strategy," is being cited by activists as a rallying cry. It argues that the challenges facing the diabetes community—from the skyrocketing cost of insulin to the stagnation of research grants—require more transparency and more debate, not less. As one of the specialists who was escorted out of the New Orleans meeting wrote in his account: "We didn’t leave our labs and our patients to go to a convention to be silent. We went there to ensure that there is a future for the next generation of researchers. If the ADA won’t let us speak in the halls or in the journals, we will find other ways to be heard." This sentiment, echoed by a growing number of professionals, suggests that the "fresh turn" in this controversy is only the beginning of a much larger struggle for the soul of the American Diabetes Association.
